How Will an Appeals Court Ruling on Ruzurgi Affect My Daughter?

How Will an Appeals Court Ruling on Ruzurgi Affect My Daughter?

308757

How Will an Appeals Court Ruling on Ruzurgi Affect My Daughter?

Most of us in the Lambert-Eaton myasthenic syndrome (LEMS) community have been following a court case involving Ruzurgi (amifampridine), the only LEMS treatment approved by the U.S. Food and Drug Administration for children under 17. In 2019, Catalyst Pharmaceuticals sued the FDA and other parties over the agency’s approval of Ruzurgi, which was developed by Jacobus Pharmaceuticals. As Lambert-Eaton News‘ Marisa Wexler noted last week, Catalyst Pharmaceuticals argued that Ruzurgi’s approval “violated the company’s right…

You must be logged in to read/download the full post.